glp-1-based therapies Q&A: Long-term success of GLP-1 hinges on more than just a prescription GLP-1 Agonists in Cardiovascular Diseases:
Description
Dean is a board-certified family medicine physician and co-founder of Trinity Family Medicine
Evidence: The SCALE clinical programme demonstrated significant benefits, with participants achieving an average weight loss of approximately 8 per cent of baseline body weight at 56 weeks, compared with around 3 per cent in those who received lifestyle intervention alone
You can, because tirzepatide does not cause physical dependence or dangerous withdrawal symptoms
By doing so, they enhance the same pathways that regulate appetite and glucose levels
